ImmuPharma的存货在较低的交易量上下降了8.3%,尽管它有可能治疗Lupus。 ImmuPharma's stock dropped 8.3% on lower trading volume, despite its potential Lupus treatment.

ImmuPharma的股票价格在星期三下跌8.3%,交易额低至GBX4.11,在GBX4.59结束。 ImmuPharma's stock price fell 8.3% on Wednesday, trading as low as GBX 4.11 and closing at GBX 4.59. 该公司开发了百草枯治疗自发免疫疾病药物,其交易量下降了65%,降至7 864 863股。 The company, which develops peptide-based therapeutics for autoimmune diseases, saw trading volume drop by 65% to 7,864,863 shares. ImmuPharma的市场上限为1 910万英镑,PE比率为-458.70。 ImmuPharma has a market cap of £19.10 million and a PE ratio of -458.70. 其牵头方案P140(LupuzorTM)是治疗Lupus和其他自发免疫疾病的一种潜在疗法。 Its lead program, P140 (Lupuzor™), is a potential treatment for Lupus and other autoimmune diseases.